Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Summary

This pilot clinical trial studies how well vismodegib works in treating patients with chronic graft-versus-host disease that did not respond to previous steroid treatment. Chronic graft-versus-host disease can cause a build-up of scar tissue under the skin and lead to symptoms such as sclerodermatous skin changes, dry mouth, dry eye, narrowing of the esophagus, or vaginal graft-versus-host disease. Vismodegib may work against the build-up of scar tissue and be a better treatment for chronic graft-versus-host disease caused by a hematopoietic stem cell transplant.

Timeline

Start

2015-09-08

Primary completion

2018-06-28

Completion

2018-06-28

Drugs

Indications